Comprehensive review of solid tumor bone marrow metastasis

Zhang, Lanxin; Chen, Fengxi; Xu, Lingzhi; Li, Ning; Zhuo, Qiping; Guo, Yijin; Wang, Xueqing; Wen, Meijie; Zhao, Zuowei; Li, Man

doi:10.1016/j.critrevonc.2023.104248

Cited by 2 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the standard combination treatment may not be suitable for patients with NPC exhibiting extensive bone marrow metastasis. Bone marrow metastasis is a poor prognostic factor in all non-hematologic malignancies ( 13 ). Patients with bone marrow metastasis typically lack specific clinical manifestations and commonly exhibit symptoms such as anemia, thrombocytopenia, bone pain, and bleeding tendencies ( 14 ).…”

Section: Discussionmentioning

confidence: 99%

“…Since bone marrow aspiration is not a routine test for solid tumors, most patients have already experienced diffuse tumor invasion in the bone marrow at the time of diagnosis. At this stage, many patients have developed fatal complications, such as severe myelosuppression, infection, and disseminated intravascular coagulation ( 13 ). This creates a treatment dilemma: these patients may struggle to tolerate the side effects of standard-dose chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis

Wang,

Yuan,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Nasopharyngeal carcinoma with bone marrow metastasis presents a rare and challenging clinical scenario associated with exceedingly poor prognosis. While standard treatment regimens offer limited efficacy and tolerability in such cases, individualized approaches are increasingly necessary. We present the case of a 64-year-old male diagnosed with recurrent nonkeratinizing undifferentiated nasopharyngeal carcinoma with extensive bone marrow metastasis (rTxN0M1). Treatment was initiated with immunotherapy-based combination therapy, consisting of pembrolizumab and low-dose cisplatin, which resulted in an initial response. Subsequently, there was a transition to standard-dose nab-paclitaxel-cisplatin chemotherapy in combination with pembrolizumab, followed by maintenance therapy with pembrolizumab plus fruquintinib. The patient achieved a sustained response with renormalization of tumor markers, imaging findings, and bone biopsies, resulting in complete remission. This case highlights the successful management of nasopharyngeal carcinoma with extensive bone marrow metastasis through an individualized treatment approach incorporating immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%